Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis

Salma A Fereig, Ghada M El-Zaafarany, Mona G Arafa, Mona M A Abdel-Mottaleb, Salma A Fereig, Ghada M El-Zaafarany, Mona G Arafa, Mona M A Abdel-Mottaleb

Abstract

Psoriasis is a dermatological chronic skin condition with underlying autoimmune etiology. It deeply affects patients' quality of life. Therefore, it was an interesting target for researchers throughout the past years. Conventionally, the treatment options include anti-inflammatory agents, immune suppressants, biologic treatment, and phototherapy. Nanotechnology offers promising characteristics that allow for tailoring a drug carrier to achieve dermal targeting, improved efficacy and minimize undesirable effects. Being the safest route, the first line of treatment and a targeted approach, we solely discussed the use of the topical route, combined with advanced drug delivery systems for the management of psoriasis in this article. Advanced systems include polymeric, metallic, lipidic and hybrid nanocarriers incorporating different active agents. All formerly mentioned types of drug delivery systems were investigated through the past decades for the purpose of topical application on psoriatic plaques. Scientists' efforts are promising to reach an optimized formula with a convenient dosage form to improve efficacy, safety, and compliance for the treatment of psoriasis. Accordingly, it will offer a better quality of life for patients.

Keywords: Hybrid; lipid; metal; polymers; psoriasis; topical.

Figures

Figure 1.
Figure 1.
Psoriatic plaques covered with silvery scales compared to normal skin parts.
Figure 2.
Figure 2.
A summary of the underlying pathogenesis of psoriatic skin lesions.
Figure 3.
Figure 3.
Various types of nanocarriers used for topical drug delivery.

References

    1. Abdel-Mottaleb MM, Lamprecht A. (2016). In vivo skin penetration of macromolecules in irritant contact dermatitis. Int J Pharm 515:384–9.
    1. Abdel-Mottaleb MM, Moulari B, Beduneau A, et al. (2012. a). Nanoparticles enhance therapeutic outcome in inflamed skin therapy. Eur J Pharm Biopharm 82:151–7.
    1. Abdel-Mottaleb MM, Moulari B, Beduneau A, et al. (2012. b). Surface-charge-dependent nanoparticles accumulation in inflamed skin. J Pharm Sci 101:4231–9.
    1. Abdel-Mottaleb MM, Neumann D, Lamprecht A. (2011). Lipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriers. Eur J Pharm Biopharm 79:36–42.
    1. Abdel-Mottaleb MM, Try C, Pellequer Y, Lamprecht A. (2014). Nanomedicine strategies for targeting skin inflammation. Nanomedicine 9:1727–43.
    1. Abdel-Mottaleb MMA. (2016). Nanoparticles for treatment of atopic dermatitis. In: Hamblin MR, Avci P, Prow TW, eds. Nanosci Dermatol. Boston (MA): Academic Press, 167–75.
    1. Abdel-Mottaleb MMA, Lamprecht A. (2016). Polymeric Nano (and Micro) Particles as Carriers for Enhanced Skin Penetration. In: Dragicevic N, Maibach HI, eds. Percutaneous penetration enhancers chemical methods in penetration enhancement: nanocarriers. Berlin (Germany); Heidelberg (Germany): Springer, 187–99.
    1. Agarwal R, Katare OP, Vyas SP. (2001). Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm 228:43–52.
    1. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. (2004). Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Contr Rel 100:5–28.
    1. Agrawal U, Gupta M, Vyas SP. (2015). Capsaicin delivery into the skin with lipidic nanoparticles for the treatment of psoriasis. Artif Cells Nanomedicine Biotechnol 43:33–9.
    1. Ahmed EM. (2015). Hydrogel: preparation, characterization, and applications: a review. J Adv Res 6:105–21.
    1. Aiswarya MU, Raju K, Menon RB, et al. (2019). Cryptosomes: a revolutionary breakthrough in novel drug delivery. Int J App Pharm 11:7.
    1. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. (2013). Liposome: classification, preparation, and applications. Nanoscale Res Lett 8:102–102.
    1. Ali I, Mukhtar SD, Lone MN, et al. (2017). Recent advances in mesoporous silica and gold based nanovectors in anticancer drug delivery system. Curr Org Chem 21:2400–15.
    1. Alves MP, Scarrone AL, Santos M, et al. (2007). Human skin penetration and distribution of nimesulide from hydrophilic gels containing nanocarriers. Int J Pharm 341:215–20.
    1. Amarji B, Garg NK, Singh B, Katare OP. (2016). Microemulsions mediated effective delivery of methotrexate hydrogel: more than a tour de force in psoriasis therapeutics. J Drug Target 24:147–60.
    1. An F-F, Zhang X-H. (2017). Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery. Theranostics 7:3667–89.
    1. Anand K, Karmakar S, Ray S, et al. (2019). Nano-emulgel: emerging as a smarter topical lipidic emulsion-based nanocarrier for skin healthcare applications. Recent Patents anti-Infect Drug Disc 14:16–35.
    1. Andrienko D. (2018). Introduction to liquid crystals. J Mol Liq 267:520–41.
    1. Anwana U. (2015). Herbosomes in the delivery of phytotherapeutics and nutraceuticals:concepts,applications and future perspective. Covenant J Phys Life Sci 3:10–22.
    1. Arafa MG, El-Kased RF, Elmazar MM. (2018). Thermoresponsive gels containing gold nanoparticles as smart antibacterial and wound healing agents. Sci Rep 8:13674.
    1. Arafa MG, Mousa HA, Afifi NN. (2020). Preparation of PLGA-chitosan based nanocarriers for enhancing antibacterial effect of ciprofloxacin in root canal infection. Drug Deliv 27:26–39.
    1. Arora R, Katiyar SS, Kushwah V, Jain S. (2017). lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: a comparative study. Expert Opin Drug Deliv 14:165–77.
    1. Baboota S, Sharma S, Kumar A, et al. (2011). Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis. Int J Pharma Investig 1:139.
    1. Badıllı U, Şen T, Tarımcı N. (2011). Microparticulate based topical delivery system of clobetasol propionate. AAPS PharmSciTech 12:949–57.
    1. Bakshi H, Nagpal M, Singh M, et al. (2020). Treatment of psoriasis: a comprehensive review of entire therapies. Curr Drug Saf 15:1–23.
    1. Balak DM. (2015). Fumaric acid esters in the management of psoriasis. Psoriasis Auckl NZ 5:9–23.
    1. Bansal S, Kashyap CP, Aggarwal G, Harikumar S. (2012). A comparative review on vesicular drug delivery system and stability issues. 10:704–13.
    1. Behera J, Keservani RK, Yadav A, et al. (2010). Methoxsalen loaded chitosan coated microemulsion for effective treatment of psoriasis. Int j Drug Delivery 2:159–67.
    1. Bessar H, Venditti I, Benassi L, et al. (2016). Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. Coll Surf B Biointerfaces 141:141–7.
    1. Bhatia S. (2016). Nanoparticles types, classification, characterization, fabrication methods and drug delivery applications. In: Bhatia S, ed. Natural polymer drug delivery systems. Cham (Switzerland): Springer International Publishing, 33–93.
    1. Boakye CHA, Patel K, Doddapaneni R, et al. (2017). Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment. J Controlled Release 246:120–32.
    1. Buchiraju R, Nama S, Sakala B, et al. (2013). Research journal of pharmaceutical. Biol Chem Sci 4:14.
    1. Buchman A. (2001). Side effects of corticosteroid therapy. J Clin Gastroenterol 33:289–94.
    1. Chen X, Hong S, Sun X, et al. (2020). Efficacy of fish oil and its components in the management of psoriasis: a systematic review of 18 randomized controlled trials. Nutr Rev 29:1–14.
    1. Crisan D, Scharffetter-Kochanek K, Crisan M, et al. (2018). Topical silver and gold nanoparticles complexed with Cornus mas suppress inflammation in human psoriasis plaques by inhibiting NF-κB activity. Exp Dermatol 27:1166–9.
    1. Crisan D. (2016). Anti-inflammatory effect of metallic silver and gold nanoparticles complexed with polyphenolic compounds in human chronic stationary plaque psoriasis [dissertation]. St Gallen (Germany): Klinik für Dermatologie und Allergologie.
    1. Crisan M, David L, Moldovan B, et al. (2013). New nanomaterials for the improvement of psoriatic lesions. J Mater Chem B 1:3152.
    1. Czarnecka-Operacz M, Sadowska-Przytocka A. (2014). The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge. Adv Dermatol Allergol 31:392–400.
    1. Danhier F, Ansorena E, Silva JM, et al. (2012). PLGA-based nanoparticles: an overview of biomedical applications. Drug Deliv Res Eur 161:505–22.
    1. Das RP, Jain A, Ramesh V. (2009). Current concepts in the pathogenesis of psoriasis. Indian J Dermatol 54:7–12.
    1. David L, Moldovan B, Vulcu A, et al. (2014). Green synthesis, characterization and anti-inflammatory activity of silver nanoparticles using European black elderberry fruits extract. Coll Surf B Biointerfaces 122:767–77.
    1. Depieri LV, Borgheti-Cardoso LN, Campos PM, et al. (2016). RNAi mediated IL-6 in vitro knockdown in psoriasis skin model with topical siRNA delivery system based on liquid crystalline phase. Eur J Pharm Biopharm 105:50–8.
    1. Desai PR, Marepally S, Patel AR, et al. (2013). Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Contr Rel 170:51–63.
    1. Desmet E, Bracke S, Forier K, et al. (2016). An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: proof-of-concept in the treatment of psoriasis. Int J Pharm 500:268–74.
    1. Doktorovová S, Araújo J, Garcia ML, et al. (2010). Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Coll Surf B Biointerf 75:538–42.
    1. Dubey S, Sharma R, Mody N, Vyas SP. (2017). Novel carriers and approaches: insight for psoriasis management. In: Ficai D, Grumezescu AM, eds. Nanostruct Novel Ther. Amsterdam, Netherlands: Elsevier, 657–84.
    1. Dudala TB, Yalavarthi PR, Vadlamudi HC, et al. (2014). A perspective overview on lipospheres as lipid carrier systems. Int J Pharma Investig 4:149–55.
    1. Eustis S, El-Sayed M. (2006). Why gold nanoparticles are more precious than pretty gold: noble metal surface plasmon resonance and its enhancement of the radiative and nonradiative properties of nanocrystals of different shapes. Chem Soc Rev 35:209–17.
    1. Fachinetto JM, Ourique AF, Lubini G, et al. (2008). Tretinoin-loaded polymeric nanocapsules: evaluation of the potential to improve the antiproliferative activities on allium cepa root-tip compared to the free drug. Lat Am J Pharm 27:668–73.
    1. Fang J-Y, Lin Y-K, Huang Z-R. (2010). Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomed 5:117–28.
    1. Fang Y-P, Huang Y-B, Wu P-C, Tsai Y-H. (2009). Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior. Eur J Pharm Biopharm 73:391–8.
    1. Ferreira M, Barreiros L, Segundo MA, et al. (2017). Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: a targeted approach for psoriasis management. Coll Surf B Biointerfaces 159:23–9.
    1. Foerster F, Bamberger D, Schupp J, et al. (2016). Dextran-based therapeutic nanoparticles for hepatic drug delivery. Nanomed 11:2663–77.
    1. Fontana MC, Rezer JFP, Coradini K, et al. (2011). Improved efficacy in the treatment of contact dermatitis in rats by a dermatological nanomedicine containing clobetasol propionate. Eur J Pharm Biopharm 79:241–9.
    1. Gabriel D, Mugnier T, Courthion H, et al. (2016). Improved topical delivery of tacrolimus: a novel composite hydrogel formulation for the treatment of psoriasis. J Contr Rel 242:16–24.
    1. Gambhire MS, Bhalekar MR, Gambhire VM. (2011). Statistical optimization of dithranol-loaded solid lipid nanoparticles using factorial design. Braz J Pharm Sci 47:503–11.
    1. Ghadially R, Reed JT, Elias PM. (1996). Stratum corneum structure and function correlates with phenotype in psoriasis. J Invest Dermatol 107:558–64.
    1. Gianak O, Kyzas G, Samanidou V, Deliyanni E. (2018). A review for the synthesis of silk fibroin nanoparticles with different techniques and their ability to be used for drug delivery. 14:339–48.
    1. Goebel ASB, Neubert RHH, Wohlrab J. (2011). Dermal targeting of tacrolimus using colloidal carrier systems. Int J Pharm 404:159–68.
    1. Golbari NM, Porter ML, Kimball AB. (2018). Current guidelines for psoriasis treatment: a work in progress. Cutis 101:10–2.
    1. González-Parra S, Daudén E. (2019). Psoriasis and depression: the role of inflammation. Actas Dermo-Sifiliográficas Engl Ed 110:12–9.
    1. Goyal R, Macri LK, Kaplan HM, Kohn J. (2016). Nanoparticles and nanofibers for topical drug delivery. J Contr Rel 240:77–92.
    1. Gupta M, Sharma V, Chauhan NS. (2017). Nanotechnology for oral delivery of anticancer drugs: an insight potential. In: Andronescu E, Grumezescu AM, eds. Nanostructures for oral medicine. Amsterdam, Netherlands: Elsevier, 467–510.
    1. Gupta R, Gupta M, Mangal S, et al. (2014). Capsaicin-loaded vesicular systems designed for enhancing localized delivery for psoriasis therapy. Artif Cells Nanomedicine Biotechnol 44:1–34.
    1. Gupta S, Kesarla R, Chotai N, et al. (2017). Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiment (DOE) for brain targeting and enhanced bioavailability. BioMed Res Int 2017:1–18.
    1. Guterres SS, Alves MP, Pohlmann AR. (2007). Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications. Drug Target Insights 2:147–57.
    1. Hans ML, Lowman AM. (2002). Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 6:319–27.
    1. Harden JL, Krueger JG, Bowcock AM. (2015). The immunogenetics of psoriasis: a comprehensive review. J Autoimmun 64:66–73.
    1. Higgins E. (2017). Psoriasis. Medicine (Baltimore) 45:368–78.
    1. Hosseinpour-Jaghdani F, Shomali T, Gholipour-Shahraki S, et al. (2017). Cornus mas: a review on traditional uses and pharmacological properties. J Complement Integr Med 14:1–9.
    1. Huang D, Wu D. (2018). Biodegradable dendrimers for drug delivery. Mater Sci Eng C 90:713–27.
    1. Hussain T, Tan B, Yin Y, et al. (2016). Oxidative stress and inflammation: what polyphenols can do for us? Oxid Med Cell Longev 2016:1–9.
    1. Ibegbu MD. (2015). Functionalised dextran nanoparticles for drug delivery to the brain. J Nanomed Nanotechnol 6:95.
    1. Jain A, Doppalapudi S, Domb AJ, Khan W. (2016). Tacrolimus and curcumin co-loaded liposphere gel: synergistic combination towards management of psoriasis. J Contr Rel 243:132–45.
    1. Jain A, Pooladanda V, Bulbake U, et al. (2017). Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis. Nanomed Nanotechnol Biol Med 13:2251–62.
    1. Jain S, Jain V, Mahajan SC. (2014). Lipid based vesicular drug delivery systems. Adv Pharm 2014:1–12.
    1. Jain S, Mittal A, K. Jain A. (2011). Enhanced topical delivery of cyclosporin-A using PLGA nanoparticles as carrier. Curr Nanosci 7:524–30.
    1. Jaiswal M, Dudhe R, Sharma PK. (2015). Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech 5:123–7.
    1. Javadzadeh Y, Azharshekoufeh Bahari L. (2017). Therapeutic nanostructures for dermal and transdermal drug delivery. In: Grumezescu AM, ed. Nano- and microscale drug delivery systems. Amsterdam, Netherlands: Elsevier, 131–46.
    1. Jawahar N, Meyyanathan S. (2012). Polymeric nanoparticles for drug delivery and targeting: a comprehensive review. Int J Health Allied Sci 1:217.
    1. Katare OP, Raza K, Singh B, Dogra S. (2010). Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian J Dermatol Venereol Leprol 76:612.
    1. Kathe K, Kathpalia H. (2017). Film forming systems for topical and transdermal drug delivery. Asian J Pharm Sci 12:487–97.
    1. Kaur A, Katiyar SS, Kushwah V, Jain S. (2017). Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. Nanomed Nanotechnol Biol Med 13:1473–82.
    1. Kaur N, Sharma K, Bedi N. (2018). Topical nanostructured lipid carrier based hydrogel of mometasone furoate for the treatment of psoriasis. Pharma Nanotechnol 6:133–43.
    1. Kemény L, Ruzicka T, Braun-Falco O. (1990). Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol Physiol 3:1–20.
    1. Kim GK. (2010). The rationale behind topical vitamin D analogs in the treatment of psoriasis: where does topical calcitriol fit in? J Clin Aesthetic Dermatol 3:46–53.
    1. Kim K-T, Kim M-H, Park J-H, et al. (2018). Microemulsion-based hydrogels for enhancing epidermal/dermal deposition of topically administered 20(S)-protopanaxadiol: in vitro and in vivo evaluation studies. J Ginseng Res 42:512–23.
    1. Knorr F, Patzelt A, Meinke MC, et al. (2019). Interactions of nanoparticles with skin. In: Gehr P, Zellner R, eds. Biological responses to nanoscale particles: molecular and cellular aspects and methodological approaches. Cham (Switzerland): Springer International Publishing, 329–39.
    1. Knudsen NØ, Rønholt S, Salte RD, et al. (2012). Calcipotriol delivery into the skin with PEGylated liposomes. Eur J Pharm Biopharm 81:532–9.
    1. Kragballe K. (1989). Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl 151:47–52.
    1. Lapteva M, Santer V, Mondon K, et al. (2014). Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways. J Contr Rel 196:9–18.
    1. Liu W, Quan P, Li Q, et al. (2018). Dextran-based biodegradable nanoparticles: an alternative and convenient strategy for treatment of traumatic spinal cord injury. Int J Nanomed 13:4121–32.
    1. Lulla A, Malhotra G, Raut P. (2004). Topical spray compositions. US Patent No. US 6,962,691 B1. .
    1. Madan J, Dua K, Khude P. (2014). Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery. Int J Pharma Investig 4:60.
    1. Manconi M, Sinico C, Caddeo C, et al. (2011). Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin. Int J Pharm 412:37–46.
    1. Mao K-L, Fan Z-L, Yuan J-D, et al. (2017). Skin-penetrating polymeric nanoparticles incorporated in silk fibroin hydrogel for topical delivery of curcumin to improve its therapeutic effect on psoriasis mouse model. Coll Surf B Biointerfaces 160:704–14.
    1. Mason TG, Wilking JN, Meleson K, et al. (2006). Nanoemulsions: formation, structure, and physical properties. J Phys: Condens Matter 18:R635–66.
    1. McClements DJ. (2012). Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft Matter 8:1719–29.
    1. Menter A, Gottlieb A, Feldman SR, et al. (2008). Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58:826–50.
    1. Michalek IM, Loring B, John SM. (2016). World Health Organization. Global Report on Psoriasis. .
    1. Miquel-Jeanjean C, Crépel F, Raufast V, et al. (2012). Penetration study of formulated nanosized titanium dioxide in models of damaged and sun-irradiated skins. Photochem Photobiol 88:1513–21.
    1. Mittal AK, Chisti Y, Banerjee UC. (2013). Synthesis of metallic nanoparticles using plant extracts. Biotechnol Adv 31:346–56.
    1. Moghassemi S, Hadjizadeh A. (2014). Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Contr Rel 185:22–36.
    1. Moghimi SM, Hunter AC. (2000). Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol 18:412–20.
    1. Mohammed MA, Syeda JTM, Wasan KM, Wasan EK. (2017). An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics 9:53.
    1. Mukherjee S, Ray S, Thakur RS. (2009). Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 71:349–58.
    1. Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 3:161–77.
    1. Murphy EC, Schaffter SW, Friedman AJ. (2019). Nanotechnology for Psoriasis Therapy. Curr Derm Rep 8:14–25.
    1. Musa SH, Basri M, Fard Masoumi HR, et al. (2017). Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action. Int J Nanomed 12:2427–41.
    1. Nam S-H, Ji XY, Park J-S. (2011). Investigation of tacrolimus loaded nanostructured lipid carriers for topical drug delivery. Bull Korean Chem Soc 32:956–60.
    1. Nemati H, Ghahramani M-H, Faridi-Majidi R, et al. (2017). Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis. J Contr Rel 268:259–68.
    1. Niska K, Zielinska E, Radomski M. (2017). Metal nanoparticles in dermatology and cosmetology: interactions with human skin cells. Chem Biol Interact 1:38–51.
    1. Ourique AF, Melero A, Bona da Silva al. (2011). Improved photostability and reduced skin permeation of tretinoin: development of a semisolid nanomedicine. Eur J Pharm Biopharm 79:95–101.
    1. Pardasani A, Feldman S, Clark A. (2000). Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician 61:725–33.
    1. Parrish JA, Jaenicke KF. (1981). Action spectrum for phototherapy of psoriasis. J Invest Dermatol 76:359–62.
    1. Patel DM, Patel C, Jani R. (2011). Ufasomes: a vesicular drug delivery. Syst Rev Pharm 2:72.
    1. Perde-Schrepler M, David L, Olenic L, et al. (2016). Gold nanoparticles synthesized with a polyphenols-rich extract from cornelian cherry (Cornus mas) fruits: effects on human skin cells. J Nanomater 2016:1–13.
    1. Pinto MF, Moura CC, Nunes C, et al. (2014). New topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers. Int J Pharm 477:519–26.
    1. Pischon H, Radbruch M, Ostrowski A, et al. (2017). Stratum corneum targeting by dendritic core-multishell-nanocarriers in a mouse model of psoriasis. Nanomed Nanotechnol Biol Med 13:317–27.
    1. Pivetta TP, Simões S, Araújo MM, et al. (2018). Development of nanoparticles from natural lipids for topical delivery of thymol: investigation of its anti-inflammatory properties. Coll Surf B Biointerfaces 164:281–90.
    1. Pradhan M, Alexander A, Singh MR, et al. (2018). Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomed Pharmacother 107:447–63.
    1. Pradhan M, Singh D, Singh MR. (2013). Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches. J Contr Rel 170:380–95.
    1. Priprem A, Limsitthichaikoon S, Thappasarapong S. (2015). Anti-inflammatory activity of topical anthocyanins by complexation and niosomal encapsulation. Int J Chem Mol Eng 9:1–5.
    1. Psomadakis CE, Han G. (2019). New and emerging topical therapies for psoriasis and atopic dermatitis. J Clin Aesthetic Dermatol 12:28–34.
    1. Puglia C, Bonina F. (2012). Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin Drug Deliv 9:429–41.
    1. Puri A, Loomis K, Smith B, et al. (2009). Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 26:523–80.
    1. Rahman M, Ahmad MZ, Kazmi I, et al. (2012) Insight into the biomarkers as the novel anti-psoriatic drug discovery tool: a contemporary viewpoint. Curr Drug Discov Technol 9:48–62.
    1. Rahman M, Akhter S, Ahmad J, et al. (2015). Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy. Expert Opin Drug Deliv 12(4):635–52.
    1. Rahman M, Akhter S, Beg S. (2018). Nanomedicine advances in topical infective and non-infective skin diseases therapy. Rec Pat Anti-Infect Drug Disc 13:104.
    1. Rahman M, Alam K, Ahmad MZ, et al. (2012). Classical to current approach for treatment of psoriasis: a review. Endocr Metab Immune Disord Drug Targets 12:287–302.
    1. Rahman M, Beg S, Ahmad MZ, et al. (2013). Omega-3 fatty acids as pharmacotherapeutics in psoriasis: current status and scope of nanomedicine in its effective delivery. Curr Drug Targ 14:708–22.
    1. Rahman M, Beg S, Akhter S. (2019) Conventional formulations, challenges and nanomedicines in infective and non-infective skin diseases therapy. Rec Pat Anti-Infect Drug Disc 14:9.
    1. Rahman M, Kumar V, Beg S, et al. (2016). Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art. Artif Cells Nanomedicine Biotechnol 44:1597–608.
    1. Rapalli VK, Singhvi G, Dubey SK, et al. (2018). Emerging landscape in psoriasis management: from topical application to targeting biomolecules. Biomed Pharmacother 106:707–13.
    1. Raza K, Singh B, Lohan S, et al. (2013). Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm 456:65–72.
    1. Rehman MU, Yoshihisa Y, Miyamoto Y, Shimizu T. (2012). The anti-inflammatory effects of platinum nanoparticles on the lipopolysaccharide-induced inflammatory response in RAW 264.7 macrophages. Inflamm Res 61:1177–85.
    1. Ridolfi DM, Marcato PD, Justo GZ, et al. (2012). Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin. Coll Surf B Biointerfaces 93:36–40.
    1. Rosado C, Silva C, Reis CP. (2013). Hydrocortisone-loaded poly(ε-caprolactone) nanoparticles for atopic dermatitis treatment. Pharm Dev Technol 18:710–8.
    1. Rosano HL, Cavallo JL, Chang DL, Whittam JH. (1987). Microemulsions: a commentary on their preparation. J Soc Cosmet Chem 9:201–9.
    1. Ruihua W. (2012). FK506-loaded solid lipid nanoparticles: preparation, characterization and in vitro transdermal drug delivery. Afr J Pharm Pharmacol 6: 904–13.
    1. Shefrin S, Sreelaxmi SC, Vijayan V, Nair SC. (2017). Enzymosomes: a rising effectual tool for targeted drug delivery system. Int J App Pharm 9:1.
    1. Sala M, Diab R, Elaissari A, Fessi H. (2018). Lipid nanocarriers as skin drug delivery systems: properties, mechanisms of skin interactions and medical applications. Int J Pharm 535:1–17.
    1. Sala M, Elaissari A, Fessi H. (2016). Advances in psoriasis physiopathology and treatments: up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). J Contr Rel 239:182–202.
    1. Salvadori M, Bertoni E. (2003). Side effects and toxicity of immunosuppressive agents. G Ital Nefrol Organo Uff Della Soc Ital Nefrol 20:490–502.
    1. Salvi VR, Pawar P. (2019). Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier. J Drug Deliv Sci Technol 51:255–67.
    1. Sano S. (2015). Psoriasis as a barrier disease. Spec Issue 5th Annu Congr Pan Asian‐Pacific Skin Barrier Res Soc PAPSBRS. 33:64–9.
    1. Sarac G, Koca TT, Baglan T. (2016). A brief summary of clinical types of psoriasis. North Clin Istanb 3:79–82.
    1. Saurat J-H. (1999). Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 41:S2–S6.
    1. Şenyiğit T, Sonvico F, Barbieri S, et al. (2010). Lecithin/chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin. J Contr Rel 142:368–73.
    1. Shankar PD, Shobana S, Karuppusamy I, et al. (2016). A review on the biosynthesis of metallic nanoparticles (gold and silver) using bio-components of microalgae: formation mechanism and applications. Enzyme Microb Technol 95:28–44.
    1. Silva LAD, Taveira SF, Lima EM, Marreto RN. (2012). In vitro skin penetration of clobetasol from lipid nanoparticles: drug extraction and quantitation in different skin layers. Braz J Pharm Sci 48:811–7.
    1. Silverman AK, Ellis CN, Voorhees JJ. (1987. May). Hypervitaminosis A syndrome: a paradigm of retinoid side effects. J Am Acad Dermatol 16:1027–39.
    1. Singhvi G, Hejmady S, Rapalli VK, et al. (2020). Nanocarriers for topical delivery in psoriasis. In: Shegokar R, ed. Del Drugs. Amsterdam, Netherlands: Elsevier, 75–96.
    1. Singka GSL, Samah NA, Zulfakar MH, et al. (2010). Enhanced topical delivery and anti-inflammatory activity of methotrexate from an activated nanogel. Eur J Pharm Biopharm 76:275–81.
    1. Soni KS, Desale SS, Bronich TK. (2016). Nanogels: an overview of properties, biomedical applications and obstacles to clinical translation. J Contr Rel 240:109–26.
    1. Srisuk P, Thongnopnua P, Raktanonchai U, Kanokpanont S. (2012. May). Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment. Int J Pharm 427:426–34.
    1. Sticherling M. (2016). Psoriasis and autoimmunity. Autoimmun Rev 15:1167–70.
    1. Suk JS, Xu Q, Kim N, et al. (2016). PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99:28–51.
    1. Sun L, Liu Z, Lin Z, et al. (2018). Comparison of normal versus imiquimod-induced psoriatic skin in mice for penetration of drugs and nanoparticles. Int J Nanomed 13:5625–35.
    1. Sun L, Liu Z, Wang L, et al. (2017). Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel. J Contr Rel 254:44–54.
    1. Tadwee IK, Gore S, Giradkar P. (2011). Advances in topical drug delivery system: a review. International Journal of Pharmaceutical Research and Allied Sciences 1:14–23.
    1. Takahashi H, Tsuji H, Minami-Hori M, et al. (2014). Defective barrier function accompanied by structural changes of psoriatic stratum corneum. J Dermatol 41:144–8.
    1. Tanaka K. (2009). The proteasome: overview of structure and functions. Proc Jpn Acad, Ser B 85:12–36.
    1. Tros de Ilarduya C, Sun Y, Düzgüneş N. (2010). Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci 40:159–70.
    1. Tucker BS, Sumerlin BS. (2014). Poly (N-(2-hydroxypropyl) methacrylamide)-based nanotherapeutics. Polym Chem 5:1566–72.
    1. Uchegbu IF, Bouwstra JA, Florence AT. (1992). Large disk-shaped structures (discomes) in nonionic surfactant vesicle to micelle transitions. J Phys Chem 96:10548–53.
    1. Venditti I. (2017). Morphologies and functionalities of polymeric nanocarriers as chemical tools for drug delivery: a review. J King Saud Univ - Sci 31:398–411.
    1. Vicentini FTMC, Depieri LV, Polizello ACM, et al. (2013). Liquid crystalline phase nanodispersions enable skin delivery of siRNA. Eur J Pharm Biopharm 83:16–24.
    1. Viswanathan P, Muralidaran Y, Ragavan G. (2017). Challenges in oral drug delivery: a nano-based strategy to overcome. In: Andronescu E, Grumezescu AM, eds. Nanostructures for oral medicine. Amsterdam, Netherlands: Elsevier, 173–201.
    1. Wadhwa S, Singh B, Sharma G, et al. (2016). Liposomal fusidic acid as a potential delivery system: a new paradigm in the treatment of chronic plaque psoriasis. Drug Deliv 23:1204–13.
    1. Wan T, Pan J, Long Y, et al. (2017. a). Dual roles of TPGS based microemulsion for tacrolimus: enhancing the percutaneous delivery and anti-psoriatic efficacy. Int J Pharm 528:511–23.
    1. Wan T, Pan W, Long Y, et al. (2017. b). Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities. Int J Nanomed 12:1485–97.
    1. Wang M, Lai X, Shao L, Li L. (2018). Evaluation of immunoresponses and cytotoxicity from skin exposure to metallic nanoparticles. Int J Nanomed 13:4445–59.
    1. Yasmin R, Shah M, Khan SA, et al. (2016). Gelatin nanoparticles: a potential candidate for medical applications. Nanotechnol Rev 6:191.
    1. Yordanov G, (2012). Poly(alkyl cyanoacrylate) nanoparticles as drug carriers 33 years later. Bulg J Chem 1:61–73.
    1. Yu K, Wang Y, Wan T, et al. (2017). Tacrolimus nanoparticles based on chitosan combined with nicotinamide: enhancing percutaneous delivery and treatment efficacy for atopic dermatitis and reducing dose. Int J Nanomed 13:129–42.
    1. Zhang J, Smith E. (2011). Percutaneous permeation of betamethasone 17-valerate incorporated in lipid nanoparticles. J Pharm Sci 100:896–903.
    1. Zhang Y-T, Feng N-P, Shen L-N, Zhao J-H. (2014). Evaluation of psoralen ethosomes for topical delivery in rats by using in vivo microdialysis. Int J Nanomedicine 9:669–678.
    1. Zhou X, Chen Z. (2015). Preparation and performance evaluation of emulsomes as a drug delivery system for silybin. Arch Pharm Res 38:2193–200.
    1. Zolotarenko A, Chekalin E, Mehta R, et al. (2017). Identification of transcriptional regulators of psoriasis from RNA-Seq experiments. In: Tatarinova TV, Nikolsky Y, eds. Biological networks and pathway analysis. New York, NY: Humana Press, 355–70.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi